Answer
Yes, transient oxygen desaturation and/or bradycardia have been reported during Survanta (beractant) dosing; if these occur, dosing should stop, appropriate measures should be initiated, and dosing should resume after stabilisation.
Sources for this answer
- Survanta 25mg/ml suspensionAbbVie Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 14Document updated
Sources checked